(non-commercial) driving licences in the Western world for UFS and recurrence of established epilepsy. We present the European situation prior to the introduction of the EU directive to highlight the heterogeneity before harmonisation.
Methods
Regulations for non-commercial driving licenses were sought from driver licensing authorities and epilepsy societies in Canada, Western Europe, Australia and New Zealand. For the USA, data were retrieved from state legislature and the state divisions or departments of motor vehicles. The sources were reviewed for the SFP required after UFS or after recurrence of known epilepsy, and for any requirement for physicians to provide statutory reports of patients with seizures. For Western European countries, the regulations prior to the implementation of EU Commission Directive 2009/112/EEC were used as the basis of the review whilst for all other countries the data is presented as at August 2011.
Pubmed and Scopus were searched using the terms ''epilepsy'' or ''seizure'' in combination with ''driv*'', ''recurrence'' or ''prognosis''. Relevant papers written in English were retrieved, and their reference lists were hand-searched for further relevant literature. Available consensus guidelines were also obtained.
Results
Most US states required a SFP of 3, 6 or 12 months whilst others employed case-by-case decisions (Fig. 1) . Legislation did not distinguish UFS and established epilepsy. Canadian provinces and territories mostly followed the guidelines of the Canadian Council of Motor Transport Administrators, 20 which stipulated a 6-month SFP, but with no restriction applying in the case of an UFS with normal neurological assessment and EEG. Quebec had separate rules specifying a 12-month SFP; again no restriction applied after an UFS with normal assessment and EEG. Statutory physician reporting was required in 6 US states (California, Delaware, Nevada, New Jersey, Oregon, Pennsylvania), and 7 Canadian provinces and territories (Manitoba, New Brunswick, Newfoundland & Labrador, Northwest Territories, Ontario, Prince Edward Island, Yukon). In Western Europe, similar variability in the SFP was observed. However, regulations were generally more stringent than in North America, requiring a SFP of up to 24 months. Several countries distinguished UFS and recurrence of established epilepsy with more restrictive regulations for the latter, except in Denmark where UFS were associated with a longer SFP. The only country in which we found evidence of mandatory physician reporting was Norway. 21 New Zealand required a 12-month SFP for UFS or recurrence of established epilepsy, which could be reduced to 6 months on the recommendation of a neurologist. In Australia, the SFP ranged from 6 months for an UFS or successful treatment of newly diagnosed epilepsy to 24 months for uncontrolled epilepsy. Shorter periods of 1 and 3 months respectively were permitted after a provoked and unprovoked recurrence of previously controlled epilepsy. Australia and New Zealand did not require mandatory reporting. This summary only touches on the complex nature of legislation surrounding driving and PWE. In many Western countries, requirements could be lessened on the recommendation of a neurologist and numerous exceptions to the regulations existed. Common themes included acute symptomatic seizures, seizures triggered by planned medication changes, seizures occurring exclusively from sleep and seizures associated with a prolonged aura. Due to their wide variety these are not reviewed further here but reference should be made to the original regulations.
Discussion
Western driving regulations for UFS and recurrence of established epilepsy remain very heterogeneous. To provide an informed context for suggesting possible improvements, we review the risks posed by people with seizures who drive, as well as previous consensus statements and apparent limitations of driving rules.
Risk of accidents
Seizure-related road traffic accidents (RTAs) are often sensationalised in the press which may result in an exaggerated public risk perception. Therefore, fundamental questions include the proportion of RTAs in PWE that are attributable to seizures, the magnitude of the increased risk of RTAs in PWE, and a comparison of this increased risk to other medical conditions or factors such as age and sex.
Although approximately half of seizures at the wheel lead to an RTA, 1 only a minority of accidents in PWE are due to seizures (11%) 22 or side effects of medication. 23 The majority are due to driver error, the same major cause as in the general population. 22 In comparison to other factors, epilepsy contributes little to increased risk of RTAs. The largest retrospective cohort study undertaken in over 30,000 US subjects reported an RR of 1.33 (1.00-1.73), which was comparable to the RR in people with diabetes 28 or medical conditions which do not carry driving restrictions, such as cardiovascular disease. The highest accident rates are seen in people without epilepsy who are young, elderly or under the influence of alcohol or drugs. The RR in PWE is far less than the fivefold increase in RTA risk seen in healthy drivers under the age of 25, 29 and the accident risk of women with epilepsy is less than that of men without epilepsy. 30 A case-control study of RTAs did not show any overrepresentation of PWE in the accident group, 31 and the lifetime risk of RTAs does not differ between those with and without epilepsy. 32 As PWE drive fewer miles than the general population, this may limit any increase in accidents and some US states use this as a basis to issue time-or distance-limited driving licences to PWE. The minimal increase in RTA risk in comparison to other risk factors is reflected in the low proportion of accidents related to seizures: between 0.02% and 0.25% of accidents are seizurerelated 17, [33] [34] [35] whilst 31% of accidents are related to alcohol. 35 Out of all medically related crashes, between 4.2% (35) and 30% (34) are caused by seizures. Sonnen estimated that, on average, a driver would be involved in an RTA with somebody having a seizure once every 4000 years. 36 Fewer accidents occur due to epilepsy than through natural death at the wheel. 
Risk of recurrence
Seizures typically cause sudden, episodic and unpredictable incapacity rather than continuous impairment. 12 Hence, physical assessment is informative in patients with either fixed (e.g. stroke) or progressive impairment (e.g. dementia), but not in PWE where fitness to drive is judged using estimates of the risk of recurrence.
Recurrence risk after a first seizure has been investigated in many observational studies and several randomised trials. 40-50% of untreated patients suffer a recurrence within 2 years of the index event, with the risk being highest immediately after the event before dropping off over time. 37 The proportion of recurrences that occur within a given time of the first seizure varies between studies, mostly because of differences in study populations and in the duration of follow-up. Most studies are ill-suited to informing an appropriate period of driving restriction after an UFS for two reasons. First, study populations often included patients who were below driving age, suffered provoked seizures or had multiple seizures before (A-C) Typical seizure-free periods (SFPs) required after an unprovoked first seizure (UFS) or recurrence of established epilepsy. For many countries/states the SFPs were identical in both cases (uniform shading). In several countries, the SFP was longer for recurrence of epilepsy than for UFS; the opposite situation applied in Denmark and Australia (striped shading indicating both SFPs). Several US states use case-by-case decisions rather than fixed SFPs (black shading). Underlined countries/states required statutory physician reporting. ascertainment. In some observational studies, part of the cohort was treated with anti-epileptic drugs (AEDs), which reduce recurrence risk by around half. 37 Results were usually reported in a format which does not allow these groups to be excluded. 40 Recurrence risk was estimated in the 12 months following a SFP of 6, 12, 18 or 24 months after the index event. After a SFP of 6 months, the 12-month recurrence risk was 18% and thus below the maximum acceptable risk of 20-40% stipulated by the EU, 13 prompting a post-UFS driving ban of 6 months to be specified in the EU directive. 41 In line with previous studies, recurrence risk decreased with increasing SFP. However, several points must be borne in mind. First, the recurrence risk estimate of 18% from Bonnett et al. 38 is a point estimate whose 95% CI (13-23%) extends beyond the risk threshold of 20% used in countries such as the UK. 42 The use of interval estimates has not been explicitly considered by public bodies, and if such estimates were used, a decision whether to apply conservative or liberal intervals would need to be made. Secondly, these figures were calculated using unstratified data. Untreated subgroups with risk factors (remote symptomatic aetiology, abnormal EEG, abnormal CT/MRI) had estimated recurrence risks of up to 32% (29-34%, 95% CI), highlighting that aggregate population estimates may not necessarily prove a good fit for a given individual. Thirdly, only patients in whom there was equipoise between immediate and delayed treatment were recruited to MESS, so those with very low or very high recurrence risk would not have been included. Hence, whilst the nature of the risk factors is backed up by many previous reports (reviewed in 37, 43, 44 ), the numerical figures of Bonnett et al. 38 should ideally be corroborated in an observational study. Finally, recruitment to the MESS study was often delayed by several weeks after the first event. Therefore, the dataset cannot illuminate the recurrence risk early in the natural history, providing no reassurance for countries that impose no driving restrictions after an UFS. Considering the above data on the risk of accidents and the risk of recurrence, it is little surprise that a reduction in the SFP from 12 to 3 months in Arizona was not associated with any significant increase in seizure-related accidents or fatalities, 34 and that there is no difference in accident rates between US states requiring a long (6-12 months) or short (3 months) SFP. 35 The findings in Arizona should generalise as the RTA fatality rate (20.9 per 100,000 population per year) is comparable to other states of the USA (range 6.4-37.9) 45 and to European countries (range 2.5-22.4 across 25 countries). 46 A literature review suggested that for an UFS, the difference between a 3-and 6-month ban would be 0.7 serious accidents and 0.1 life per million population. 
Risk analysis
Risk analysis involves several factors other than recurrence risk: the amount of time spent on the road, the probability and rate of onset of incapacity, the probability of incapacity leading to an RTA, and the likely outcome of an RTA. Numerical data on these factors are scarce and risk analyses therefore heavily rely on assumptions. For example, given a 20% probability of seizure in the next year for a group 1 driver, 3% time spent on the road and one fatality from every 10 RTAs, the increase in annual fatalities in the UK would be 20, but this figure would vary between 5 and 70 if more optimistic or pessimistic assumptions were used. 12 The process of risk analysis provides some reassurance that decisions are not made arbitrarily but its inherent limitations must be appreciated. Nevertheless this approach was adopted for the recent EU directive. Individualised risk models would ultimately be desirable, yet they are unlikely to be forthcoming in the near future and may not prove affordable. 8 Special exceptions for patients with seizures occurring only from sleep or with consistent and reliable auras reflect a first, pragmatic step in this direction, 47 but -at least in the case of purely sleep-related epilepsy -the evidence base for current exceptions remains uncomfortably thin. 48 Licensing conditions other than a ban from driving can be imposed in some countries, for example Australia, and include restricting the number of passengers or prohibiting motorway driving. 49 
Consensus statements
Several consensus statements have been published. Following a meeting in 1991, the American Academy of Neurology, Epilepsy Foundation of America and American Epilepsy Society jointly proposed a SFP of only 3 months with no distinction between UFS and recurrent seizures in PWE. 50 This interval could be altered by both favourable and unfavourable modifiers, for example seizures with a consistent and prolonged aura or those provoked by change in medication or acute illness. Mandatory reporting was opposed. These suggestions appear to have had little impact. In Canada, a symposium in 1998 concluded that ''a 6-12-month SFP was appropriate'' and that ''mandatory reporting should be abolished''. 51 Most Canadian provinces and territories have since adopted more relaxed standards but many continue to require mandatory reporting. Both North American statements are however now quite dated. European workshops were arranged by the International League Against Epilepsy (ILAE) in 1995 52 and the International Bureau for Epilepsy (IBE) in 1996. 36 Their recommendations based on defined SFPs were not implemented. In 2000, the European Council initiated a review of medical standards for drivers. The risk assessment considered the risk to the patient rather the population and used estimates of the percentage of seizures occurring during the day (50%), time spent at the wheel (60 min a day, based on the whole population rather than in PWE who may drive less), the proportion of seizures leading to an accident (60%) and the outcome of accidents. An annual seizure risk of 20-40% was deemed acceptable; this corresponds to a relative accident risk of 3, equivalent to that of a driver aged over 75 years as compared to a 45-54-year-old driver. The review recommended SFPs of 6 and 12 months for UFS and recurrence of established epilepsy, respectively, along with exceptions for seizures which were simple partial, provoked or occurring solely from sleep. A Commission Directive enacted these standards in 2009, 41 aiming to foster harmonisation whilst allowing individual states to be more restrictive. Although it was to be implemented within 1 year in all EU countries, uptake has been slow and remains partial.
Mandatory reporting
Mandatory reporting still exists in parts of the USA, Canada and Western Europe. This is despite opposition in the above position statements 50, 51, 53, 54 and by the ILAE and IBE. 18 The ethical arguments have been rehearsed extensively elsewhere. 55, 56 In brief, the rationale for reporting is to reduce the risk to the patient and the population. However, a comparison of two provinces in Canada with different legislation showed that mandatory reporting did not reduce accident rate. 32 Furthermore, it interferes with the doctor-patient relationship, causing breach of confidentiality and decreased reporting of seizures by the patient to the physician. The failure to report seizures may compromise care 57 and mandatory reporting leads to fewer patients being counselled regarding driving restrictions. 58 It also makes physicians potentially liable for failing to report patients who continue to drive despite ongoing seizures.
Further limitations of driving regulations
The effectiveness of driving restrictions is also constrained by seizure recognition, patient compliance and physician care. Recognition of seizures by patients is limited. Approximately half the events detected on video telemetry during surgery workup remain unreported by the patient. 59, 60 The proportion of unreported events is particularly high for complex partial (73%) or nocturnal seizures (86%). 60 Compliance with driving regulations amongst PWE has been reported to vary from 14 to 57% in Canada, Belgium, the Netherlands and New Zealand. 13, [61] [62] [63] In a Belfast study of 104
consecutive PWE, only 34 were able to state the law correctly, 3 of 75 patients who were ineligible to drive did so regardless, and 8 patients had driven illegally at some point. 64 In a UK cohort of PWE, of whom 11% had had an RTA in the prior year, only 27% complied with the physician's verbal and written advice to report to the driving authority. 65 Physician knowledge and counselling are further limiting factors. A survey amongst doctors of all grades in Belfast found that only 18% knew the correct driving regulations for PWE, 66 and a US study demonstrated that only one-third to one-half of PWE recalled being counselled about the risks of driving. 58 Finally, fewer than half of all epileptic seizures occur in the context of established epilepsy 10 and 15% of seizure-related RTAs are due to a first seizure 52 thus restricting the effectiveness of any legislation.
Conclusion
Driving is a key concern for patients with seizures. Appropriate legislation should enable this without an undue increase in RTA risk, thereby balancing maximisation of safety and minimisation of any social and financial detriments to individuals and society.
Historically, seizures often entailed total bans from driving, but restrictions have become less stringent as evidence of the low accident risk has accumulated. Indeed, the increase in accident risk seen in PWE is minimal. Its magnitude is comparable to that seen in other medical conditions such as diabetes, lower than that seen in young drivers and insignificant when compared to drinkdriving. Recurrence risk is highest in the immediate period after a seizure, and there is now sound data quantifying this risk after an UFS. However, many other variable entering a risk analysis are less well-defined, and results must therefore be interpreted with caution.
Western driving regulations for patients with seizures remain highly variable with SFPs ranging from 3 to 24 months. European legislation based on risk analysis has mandated the introduction of a 6-month SFP for an UFS and 12 months for recurrence of established epilepsy. Uptake has been slow, and legislation remains discrepant in the rest of the world. There is particularly variability in the USA reflecting greater independence of states and a lack of an overarching drive for standardisation.
There remains considerable room for improving Western driving regulations for patients with seizures. The data suggest that in the absence of adverse risk factors a reduction of the SFP to 3 months is unlikely to lead to an unacceptable increase in accidents. Observational studies to date are limited in scope and collaborative sharing of routine data between national driving authorities, motor insurance companies and police would yield high quality data to inform future risk models and legislation. Whilst our review specifically addresses Western countries, other countries should adopt a similar approach. It must be appreciated that driving is intrinsically risky, and excess risk can only be minimised but not eliminated, and it is likely that deficiencies in the recognition of events, in counselling and in compliance will remain.
